Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

BIOLOGICAL3 trials

Sponsors

Takeda

Conditions

Dengue FeverHealthy

Phase 1

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

CompletedNCT01542632

Start: 2012-02-01End: 2014-01-10Updated: 2019-07-18

Phase 2

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

CompletedNCT02302066

TakedaDengue Fever

Start: 2014-12-05End: 2019-02-18Updated: 2020-02-24

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

CompletedNCT02425098

TakedaDengue Fever

Start: 2015-06-03End: 2017-09-18Updated: 2019-08-28

Related Papers

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine

Expert Review of Vaccines2025-03-184 citations

Overcoming challenges of developing a live-attenuated dengue vaccine and the path forward

International Journal of Infectious Diseases2025-02-28

IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial

American Journal of Tropical Medicine and Hygiene2024-05-283 citations

Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.

2022-01-2217 citations

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)

PLoS neglected tropical diseases2021-03-1263 citations

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

The Journal of Infectious Diseases2021-01-2913 citations

Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine

The Journal of Infectious Diseases2020-06-1815 citations

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.

2020-03-1771 citations

Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial.

2019-12-1342 citations

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.

2017-11-0662 citations

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

2017-03-3065 citations